|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Apr―05 |
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine |
Sarah Conway, Shrishti Saxena, Clare Baecher-Allan, Rajesh Krishnan, Maria Houtchens, Bonnie Glanz, et al. (+15) Taylor J Saraceno, Mariann Polgar-Turcsanyi, Gauruv Bose, Rohit Bakshi, Shamik Bhattacharyya, Kristin Galetta, Tamara Kaplan, Christopher Severson, Tarun Singhal, Lynn Stazzone, Jonathan Zurawski, Anu Paul, Howard L Weiner, Brian C Healy, Tanuja Chitnis |
2 |
[GO] |
2022―May―23 |
Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis |
Ruth Ann Marrie, Casandra Dolovich, Gary R Cutter, Robert J. Fox, Amber Salter |
3 |
[GO] |
2022―May―04 |
Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance |
Paola Zaratin, Brenda Banwell, Timothy Coetzee, Giancarlo Comi, Anthony Feinstein, Robert Hyde, et al. (+2) Marco Salvetti, Kathryn Smith |
4 |
[GO] |
2022―Mar―22 |
Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis |
Tirisham V. Gyang, John P. Evans, Joseph S. Miller, Kariss Alcorn, Juan Peng, Erica H. Bell, et al. (+4) Cong Zeng, Richard Gumina, Shan-Lu Liu, Benjamin M. Segal |
5 |
[GO] |
2022―Mar―07 |
Perspectives and experiences with COVID-19 vaccines in people with MS |
John R. Ciotti, Dana C. Perantie, Brandon P. Moss, Kathryn C. Fitzgerald, Jeffrey A. Cohen, Ellen M. Mowry, et al. (+2) Robert T. Naismith, Salim Chahin |
6 |
[GO] |
2021―Nov―29 |
Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America |
Ricardo Alonso, Aníbal Chertcoff, Felisa del V Leguizamón, Lorna Galleguillos Goiry, Maria B Eizaguirre, Roberto Rodríguez, et al. (+10) Marta Sosa, Susana Carballido, Verónica Cruchet, Agnes de Jong-Martis, Susana Giachello, Paula Henestroza, Flavia Ferrandina, Johana Bauer, Adriana Carrá, Berenice A Silva |
7 |
[GO] |
2021―Nov―29 |
Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy |
Audrey Rico, Laetitia Ninove, Adil Maarouf, Clémence Boutiere, Pierre Durozard, Sarah Demortiere, et al. (+6) Paola Mariela Saba Villarroel, Abdennour Amroun, Toscane Fourié, Xavier de Lamballerie, Jean Pelletier, Bertrand Audoin |
8 |
[GO] |
2021―Nov―26 |
Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis |
Deja R Rose, Ahmad Z Mahadeen, Alise K Carlson, Sarah M Planchon, Jennifer Sedlak, Scott Husak, et al. (+3) Robert A Bermel, Jeffrey A Cohen, Brandon P Moss |
9 |
[GO] |
2021―Aug―27 |
Research interrupted: The impact of the COVID-19 pandemic on multiple sclerosis research in the field of rehabilitation and quality of life |
Rebecca Maguire, Sinead Hynes, Barbara Seebacher, Valerie J Block, Kathy M Zackowski, Johanna Jonsdottir, et al. (+6) Marcia Finlayson, Prue Plummer, Jennifer Freeman, Barbara Giesser, Gloria von Geldern, Michelle Ploughman |
10 |
[GO] |
2021―May―31 |
COVID-19 vaccination willingness among people with multiple sclerosis |
Xinran M Xiang, Chris Hollen, Qian Yang, Barbara H Brumbach, Rebecca I Spain, Lindsey Wooliscroft |
11 |
[GO] |
2021―Feb―26 |
Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic |
Marisa P McGinley, Shauna Gales, William Rowles, Zhini Wang, Wan-Yu Hsu, Lilyana Amezcua, Riley Bove |
12 |
[GO] |
2020―Oct―12 |
Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic |
Monica Margoni, Paolo Gallo |
13 |
[GO] |
2020―Aug―11 |
Fatal COVID-19 in an MS patient on natalizumab: A case report |
Kathryn Rimmer, Rebecca Farber, Kiran Thakur, Genna Braverman, Dina Podolsky, Lauren Sutherland, et al. (+7) Christopher Migliore, Yun Kyoung Ryu, Seth Levin, Philip L De Jager, Wendy Vargas, Libby Levine, Claire S Riley |
|